{
    "clinical_study": {
        "@rank": "90983", 
        "brief_summary": {
            "textblock": "OBJECTIVES: I.  Provide epoprostenol (Flolan, prostaglandin I2) by chronic infusion to\n      patients with severe primary pulmonary hypertension for whom no alternative therapy is\n      available.\n\n      II.  Obtain additional safety information on continuous infusion epoprostenol. III.  Obtain\n      additional information on economic resource health consumption."
        }, 
        "brief_title": "Phase IV Study of Chronic Infusional Epoprostenol for Severe Primary Pulmonary Hypertension", 
        "condition": "Hypertension, Pulmonary", 
        "condition_browse": {
            "mesh_term": [
                "Hypertension, Pulmonary", 
                "Hypertension"
            ]
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE: Patients are treated with a chronic continuous infusion of epoprostenol.\n\n      The highest tolerated infusion rate is determined for each patient by gradually increasing\n      the rate until the target dose is reached or the patient experiences at least 1\n      dose-limiting effect.\n\n      Patients are subsequently treated with a chronic continuous infusion, beginning at a rate\n      below the highest tolerated rate.  Attempts are made to increase the dose to the highest\n      tolerated rate over the first 72 hours."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n          -  Severe primary pulmonary hypertension\n\n          -  Able to prepare and self-administer medication"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "firstreceived_date": "February 24, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004754", 
            "org_study_id": "199/11678", 
            "secondary_id": "BCM-P1850"
        }, 
        "intervention": {
            "intervention_name": "epoprostenol", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Epoprostenol", 
                "Tezosentan"
            ]
        }, 
        "keyword": [
            "cardiovascular and respiratory diseases", 
            "hypertensive disorder", 
            "primary pulmonary hypertension", 
            "rare disease"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "overall_official": {
            "affiliation": "Baylor College of Medicine", 
            "last_name": "Adaani E. Frost", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 4", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004754"
        }, 
        "source": "Office of Rare Diseases (ORD)", 
        "sponsors": {
            "collaborator": {
                "agency": "Baylor College of Medicine", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "National Center for Research Resources (NCRR)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "August 1993", 
        "study_design": "Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2001"
    }, 
    "geocoordinates": {}
}